Group 1 - The third extraordinary general meeting of shareholders was held on November 13, 2025, at the company's conference room in Chongqing [2] - All 12 current directors attended the meeting, along with the board secretary and other senior management [3] - The meeting was convened and presided over by the chairman, Mr. Yu Min, and complied with the relevant provisions of the Company Law and the Articles of Association [2][3] Group 2 - Two non-cumulative voting proposals were reviewed and approved: the proposal to add a director and the proposal to change the registered capital and amend the Articles of Association [4] - The second proposal was a special resolution that required more than two-thirds of the voting rights to pass, which it achieved [5] Group 3 - The meeting was witnessed by lawyers from Taihe Tai (Chongqing) Law Firm, who confirmed that the meeting's procedures and resolutions were in compliance with legal requirements [6]

泰和泰（重庆）律师事务所 关于 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会 之 法律意见书 中国 • 重庆市两江新区财富大道 1 号财富金融中心 36 层 36/F, Fortune Financial Center, No. 1 Fortune Avenue Liangjiang New Area, Chongqing, People's Republic of China 电话| TEL: 86-23-67887666 www.tahota.com 关于 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会 之 法律意见书 （2025）泰律意字（太极集团）第 002 号 致：重庆太极实业（集团）股份有限公司 一、本次股东会的召集、召开程序及召集人资格 （一）经核查，公司于 2025 年 10 月 25 日在《上海证券报》《中 国证券报》《证券时报》《证券日报》和上海证券交易所网站 （www.sse.com.cn）上公告了《重庆太极实业（集团）股份有限公司 关于召开 2025 年第三次临时股东会的通知》（以下简称"《会议通 知》"），该通知公告了本次股东会的召开时间、地点、审议 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 13 日 (二)股东会召开的地点：重庆市渝北区恒山东路 18 号公司 1201 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 630 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 171,633,634 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 31.1258 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 证券代码：600129 证券简称：太极集团 公告编号：2025-086 重庆太极实业（集团）股份有限公司 2025年第三次临时股东会决议公告 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | ...

Group 1 - The company stated that its stock price is influenced by various factors, including internal factors such as operational performance and development potential, as well as external factors like macroeconomic conditions, market fluctuations, and investor confidence [2] - The company emphasized its commitment to fulfilling information disclosure obligations in accordance with the relevant requirements of the Shanghai Stock Exchange [2]

Core Viewpoint - Taiji Group emphasizes its commitment to maintaining shareholder interests and enhancing investor confidence through strategic actions in the capital market [2] Group 1: Company Actions - The company held the 30th meeting of the 10th Board of Directors on July 16, 2025, and the second extraordinary general meeting of shareholders on August 6, 2025, to review and approve relevant proposals [2] - On September 22, 2025, the company completed a share buyback, utilizing a total of 120 million yuan [2] Group 2: Future Plans - The company plans to consider various factors such as market conditions, regulatory requirements, and investor needs to fulfill its responsibilities as a listed company [2] - Taiji Group aims to strengthen compliance information disclosure, focus on the pharmaceutical and health sector, accelerate technological innovation, improve corporate governance, and enhance investor relations management [2]

Core Viewpoint - Taiji Group emphasizes the importance of market capitalization management, which includes governance standardization, value creation enhancement, quality information disclosure, investor relations management, and reasonable shareholder dividend policies [2]. Group 1 - The company aims to consider various factors such as market conditions, regulatory requirements, and investor needs in its capital market performance [2]. - The goal is to "improve quality and efficiency while returning value" to actively protect investor rights [2]. - The company encourages stakeholders to pay attention to its announcements for specific updates [2].

Core Viewpoint - Taiji Group focuses on the production and sales of traditional Chinese and Western medicine, emphasizing key areas in health products and a diverse product matrix [2] Company Overview - The company operates in the "4+1" key areas: digestive metabolism medications, respiratory antibiotics, cardiovascular drugs, and narcotic anti-tumor medications, along with health products [2] - Notable products include: - Digestive metabolism: Taiji Huoxiang Zhengqi Oral Liquid, Tai Luo [2] - Respiratory antibiotics: Acute Support Syrup, Sinusitis Oral Liquid [2] - Cardiovascular: Tongtian Oral Liquid, Danshen Oral Liquid [2] - Narcotic anti-tumor: Morphine Sustained Release Tablets, Lofentanil Sustained Release Tablets, Xiaojin Tablets [2] - The health product matrix includes high-end refined medicinal slices and various derivative products such as herbal teas and throat lozenges [2]

重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会会议资料 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会资料 2025 年 11 月 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会会议资料 目录 一、关于增补公司董事的议案...................................3 二、关于变更注册资本暨修订《公司章程》的议案.......... 4 1 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会会议资料 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会议程 重庆太极实业（集团）股份有限公司 2025 年 11 月 13 日 2 一、主持人宣布会议开始； 二、主持人报告股东现场到会情况； 三、到会股东审议如下议案： 1.关于增补公司董事的议案； 2.关于变更注册资本暨修订《公司章程》的议案。 四、会议讨论； 五、股东及其委托代理人对相关议案投票表决； 六、表决统计； 七、见证律师宣读法律意见书； 八、到会董事在会议决议上签字； 九、主持人宣布会议结束。 重庆太极实业（集团）股份有限公司 2025 年第三次临时股东会会议 ...

Core Insights - The article highlights the strategic transformation and international expansion of Taiji Group, showcasing its improved financial performance and operational efficiency [1][2][3]. Financial Performance - In the first three quarters of 2025, Taiji Group reported a revenue of 8.088 billion yuan and a net profit attributable to shareholders of 166 million yuan [2]. - The third quarter alone saw a revenue of 2.430 billion yuan, with a net profit of 27.108 million yuan, indicating a narrowing year-on-year revenue decline to 7.13% from 27.6% in the first half of the year [2]. - The operating cash flow for the first three quarters was 166 million yuan, matching the net profit, with a significant improvement in cash flow per share from -1.24 yuan to 0.3 yuan, a year-on-year increase of 124.34% [2][3]. Operational Efficiency - Taiji Group's inventory turnover rate averaged 2.80 times per year, and total asset turnover averaged 0.70 times per year, indicating strong operational efficiency [2]. - The company successfully reduced its total expenses to 1.888 billion yuan, with the expense ratio dropping by 30.37% year-on-year, reflecting effective cost management [3]. International Expansion - Taiji Group has successfully registered over 30 product specifications in more than 20 countries, obtaining nearly 100 overseas registration approvals [4]. - The flagship product, Huoxiang Zhengqi Oral Liquid, has played a pivotal role in the company's international strategy, gaining market access in regions like Macau and Canada [4][5]. Strategic Initiatives - The company is transitioning its Huoxiang Zhengqi product line from a seasonal remedy to a year-round health product, broadening its market appeal [5]. - Taiji Group is embracing digital transformation with the "AI Digital Taiji" initiative, focusing on data-driven decision-making and marketing innovations [7]. Market Positioning - The company has positioned its products to cater to younger consumers, integrating them into lifestyle choices, such as pairing with local cuisine [6]. - Taiji Group's commitment to ESG principles is highlighted by its inclusion in the "2025 ESG Action Report," showcasing its leadership in corporate social responsibility [7].

Core Viewpoint - The recent quarterly reports from listed companies reveal a significant shift in investment strategies among prominent private equity managers, with an increased focus on cyclical industries and a need to monitor fundamental developments, policy benefits, and industrial upgrades as core themes [1][4]. Private Equity Holdings - Gao Yi Asset's Feng Liu significantly reduced holdings in Hikvision by 58 million shares, retaining 280 million shares valued at 8.826 billion yuan, making it the fourth-largest shareholder [1]. - Renqiao Asset's Xia Junjie maintained positions in several stocks while slightly reducing holdings in Xingfu Electronics and increasing stakes in Beijing Renli [1]. - Ningquan Asset's Yang Dong entered as the eighth-largest shareholder in Fuanna with 6.0512 million shares valued at 4.2 million yuan [2]. - Ruijun Asset's funds became top shareholders in Dinglong Co., while also increasing stakes in other companies [2]. Increased Focus on Cyclical Industries - Gao Yi Asset's Deng Xiaofeng reduced holdings in Zijin Mining by approximately 18.6 million shares, still holding 180 million shares valued at 5.3 billion yuan, with a significant gain of about 1.5 billion yuan from the position [3]. - The same fund also reduced its stake in Yun Aluminum, holding 28.5 million shares valued at 1.164 billion yuan [3]. Policy Benefits and Industrial Upgrades - The Shanghai Composite Index surpassed 4,000 points, reflecting improved market sentiment and recognition of the value reassessment cycle in Chinese equity assets [4]. - Fengjing Capital noted that economic data remains resilient, with expectations for moderate improvement in fixed investment growth due to policy initiatives [4]. - Ning Shui Capital emphasized the importance of policy benefits and industrial upgrades as core investment themes while advising caution regarding high valuations [4].